Knight Therapeutics(TSE:GUD)
CA$12.03+0.05 (+0.42%)
TSE:GUD
Knight Therapeutics financials statements
CA$12.03
At close:+0.05 (+0.42%)
Want to see TSE:GUD full AI Analyst Report?
Knight Therapeutics (GUD) Financial Statements
112 Followers
Knight Therapeutics Financial Overview
Knight Therapeutics's market cap is currently C$1.18B. The company's EPS TTM is C$0.16; its P/E ratio is 77.56; Knight Therapeutics is estimated to report earnings on March 25, 2027, and the estimated EPS forecast is C$0.06. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | C$ 450.09M | C$ 371.30M | C$ 328.20M | C$ 293.56M | C$ 243.48M |
| Gross Profit | C$ 150.74M | C$ 174.41M | C$ 152.65M | C$ 138.06M | C$ 115.41M |
| Operating Income | C$ -2.20M | C$ 7.40M | C$ -2.89M | C$ -2.40M | C$ -5.32M |
| EBITDA | C$ 54.37M | C$ 64.38M | C$ 40.90M | C$ 25.26M | C$ 42.59M |
| Net Income | C$ -5.37M | C$ 4.33M | C$ -16.84M | C$ -29.89M | C$ 15.68M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | C$ 95.28M | C$ 172.84M | C$ 154.42M | C$ 185.61M | C$ 162.99M |
| Total Assets | C$ 1.05B | C$ 963.80M | C$ 945.49M | C$ 1.05B | C$ 991.89M |
| Total Debt | C$ 77.91M | C$ 49.46M | C$ 69.09M | C$ 77.70M | C$ 40.96M |
| Net Debt | C$ 1.46M | C$ -30.65M | C$ 10.33M | C$ 6.02M | C$ -45.01M |
| Total Liabilities | C$ 279.03M | C$ 168.69M | C$ 198.62M | C$ 228.98M | C$ 149.87M |
| Stockholders' Equity | C$ 767.27M | C$ 795.11M | C$ 746.87M | C$ 825.86M | C$ 842.02M |
| Cash Flow | |||||
| Free Cash Flow | C$ 68.40M | C$ 4.81M | C$ 25.98M | C$ 14.66M | C$ -179.56M |
| Operating Cash Flow | C$ 70.30M | C$ 36.28M | C$ 35.94M | C$ 40.48M | C$ 44.62M |
| Investing Cash Flow | C$ -84.11M | C$ 16.96M | C$ 29.34M | C$ -63.08M | C$ -105.28M |
| Financing Cash Flow | C$ 13.01M | C$ -33.54M | C$ -81.00M | C$ 1.76M | C$ -78.31M |
Currency in CAD
